LAWSUITS NEWS & LEGAL INFORMATION
AEterna Zentaris Inc, AEZS Securities Lawsuit
|Company:||AEterna Zentaris Inc,|
|Class Period:||Feb-3-10 to Apr-1-12|
|Lead Plaintiff Deadline:||Aug-14-12|
|Court:||Southern District of New York|
AEterna, AEterna's Chief Executive Officer Juergen Engel and AEterna's Chief Financial Officer Dennis Turpin are charged with violations of Section 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the complaint alleges that defendants mislead investors about the timing and success of AEterna's clinical trial that tested whether the drug perifosine was effective in treating late stage colorectal cancer.
On April 2, 2012, AEterna shocked the market by disclosing that perifosine was ineffective in treating colorectal cancer. This news caused AEterna stock to drop approximately 66% by the close of the business day.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
AEterna Zentaris Inc, AEZS Securities Fraud Legal HelpIf you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible AEterna Zentaris Inc, securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.
Published on Jun-18-12
READ MORE Securities Settlements and Legal News